You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 7, July 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 97TH ANNUAL MEETING OF THE WESTERN SURGICAL ASSOCIATION, ST LOUIS, MO, NOVEMBER 14 TO NOVEMBER 15, 1989-PA RT I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Radioimmune Localization of Occult Carcinoma

Rosemary B. Duda, MD; A. Michael Zimmer, PhD; Steven T. Rosen, MD; Katherine A. Gilyon, RN; Stewart Spies, MD; William Spies, MD; Bruce Merchant, MD, PhD

Arch Surg. 1990;125(7):866-870.


Abstract

• Patients with a rising serum carcinoembryonic antigen level and no clinical or roentgenographic evidence of recurrent or metastatic cancer present a treatment dilemma. Eleven such patients, 10 with a previously treated colorectal carcinoma and 1 with a previously treated breast carcinoma, received an injection of the anticarcinoembryonic antigen monoclonal antibody ZCE-025 labeled with the radioisotope indium 111. Nuclear scintigraphy was performed on days 3 and 5 through 7 to detect potential sites of tumor recurrence. The monoclonal antibody scan accurately predicted the presence or absence of occult malignancy in 7 (64%) patients. Second-look laparotomy confirmed the monoclonal antibody scan results in the patients with colorectal cancer, and magnetic resonance imaging confirmed metastatic breast cancer. This study demonstrates that In-ZCE-025 can localize occult carcinoma and may assist the surgeon in facilitating the operative exploration. In-ZCE-025 assisted in the initiation of adjuvant therapy for the patient with breast cancer.

(Arch Surg. 1990;125:866-870)



Author Affiliations

Denise Webber

From the Departments of Surgery (Dr Duda), and Medicine (Dr Rosen and Ms Gilyon) and the Division of Nuclear Medicine (Drs Zimmer, S. Spies, and W. Spies and Ms Webber), Northwestern University Medical School, Northwestern Memorial Hospital, Chicago, Illinois; and Hybritech Inc, San Diego, Calif (Dr Merchant).


Footnotes

Accepted for publication April 20, 1990.

Read before the 97th Annual Meeting of the Western Surgical Association, St Louis, Mo, November 13, 1989.

Reprint requests to Department of Surgery, Northwestern University Medical School, 250 E Superior St, Wesley 201, Chicago, IL 60611 (Dr Duda).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Detection of Occult Tumor Using Indium 111-Labeled Anticarcinoembryonic Antigen Antibodies
Halpern et al.
Arch Surg 1992;127:1094-1100.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.